GLSI

Company Overview — What Does Greenwich LifeSciences, Inc. Do?

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas. Greenwich LifeSciences, Inc. (GLSI) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Snehal S. Patel and employs approximately 3 people. With a market capitalization of $318M, GLSI is one of the notable companies in the Healthcare sector.

Greenwich LifeSciences, Inc. (GLSI) Stock Rating — Reduce (April 2026)

As of April 2026, Greenwich LifeSciences, Inc. receives a Reduce rating with a composite score of 36.3/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.GLSI ranks #3,584 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Greenwich LifeSciences, Inc. ranks #572 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

GLSI Stock Price and 52-Week Range

Greenwich LifeSciences, Inc. (GLSI) currently trades at $25.60. The stock lost $0.22 (0.9%) in the most recent trading session. The 52-week high for GLSI is $34.10, which means the stock is currently trading -24.9% from its annual peak. The 52-week low is $7.78, putting the stock 229.0% above its annual trough. Recent trading volume was 82K shares, suggesting relatively thin trading activity.

Is GLSI Overvalued or Undervalued? — Valuation Analysis

Greenwich LifeSciences, Inc. (GLSI) carries a value factor score of 33/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 142.73x, versus the sector average of 2.75x.

At current multiples, Greenwich LifeSciences, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Greenwich LifeSciences, Inc. Profitability — ROE, Margins, and Quality Score

Greenwich LifeSciences, Inc. (GLSI) earns a quality factor score of 13/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -645.5%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -370.5% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

GLSI Debt, Balance Sheet, and Financial Health

Greenwich LifeSciences, Inc. has a debt-to-equity ratio of 74.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 2.35x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $4M.

GLSI has a beta of 1.36, meaning it is more volatile than the broader market — a $10,000 investment in GLSI would be expected to move 35.9% more than the S&P 500 on any given day. The stability factor score for Greenwich LifeSciences, Inc. is 28/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Greenwich LifeSciences, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Greenwich LifeSciences, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.30. Net income for the quarter was $-14M. Operating income came in at $-14M.

In Q3 2025, Greenwich LifeSciences, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.30. Net income for the quarter was $-4M. Operating income came in at $-4M.

In Q2 2025, Greenwich LifeSciences, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.30. Net income for the quarter was $-4M. Operating income came in at $-4M.

In Q1 2025, Greenwich LifeSciences, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.25. Net income for the quarter was $-3M. Operating income came in at $-3M.

Over the past 8 quarters, Greenwich LifeSciences, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing GLSI stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

GLSI Dividend Yield and Income Analysis

Greenwich LifeSciences, Inc. (GLSI) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

GLSI Momentum and Technical Analysis Profile

Greenwich LifeSciences, Inc. (GLSI) has a momentum factor score of 68/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 50/100 reflects moderate short selling activity.

GLSI vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Greenwich LifeSciences, Inc. (GLSI) ranks #572 out of 838 stocks based on the Blank Capital composite score. This places GLSI in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing GLSI against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full GLSI vs S&P 500 (SPY) comparison to assess how Greenwich LifeSciences, Inc. stacks up against the broader market across all factor dimensions.

GLSI Next Earnings Date

No upcoming earnings date has been announced for Greenwich LifeSciences, Inc. (GLSI) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy GLSI? — Investment Thesis Summary

The quantitative profile for Greenwich LifeSciences, Inc. suggests caution. The quality score of 13/100 flags below-average profitability. The value score of 33/100 indicates premium valuation. Price momentum is positive at 68/100, suggesting the trend favors buyers. High volatility (stability score 28/100) increases portfolio risk.

In summary, Greenwich LifeSciences, Inc. (GLSI) earns a Reduce rating with a composite score of 36.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on GLSI stock.

Related Resources for GLSI Investors

Explore more research and tools: GLSI vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare GLSI head-to-head with peers: GLSI vs AZN, GLSI vs SLGL, GLSI vs VMD.